Expanding anti-CD38 immunotherapy for lymphoid malignancies

[1]  M. Kersten,et al.  Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma , 2021, Blood advances.

[2]  H. Goldschmidt,et al.  Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.

[3]  Xu Wang,et al.  MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymphomagenesis. , 2020, Blood.

[4]  Xu Wang,et al.  Targeting PD-L1 in non-small cell lung cancer using CAR T cells , 2020, Oncogenesis.

[5]  A. Yen,et al.  Roscovitine enhances all-trans retinoic acid (ATRA)-induced nuclear enrichment of an ensemble of activated signaling molecules and augments ATRA-induced myeloid cell differentiation , 2020, Oncotarget.

[6]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[7]  Michael L. Wang,et al.  Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. , 2019, Clinical lymphoma, myeloma & leukemia.

[8]  F. Malavasi,et al.  CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma , 2018, Front. Immunol..

[9]  S. Usmani,et al.  CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance , 2018, Front. Immunol..

[10]  G. Ossenkoppele,et al.  CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia , 2018, Haematologica.

[11]  E. Dmitrovsky,et al.  CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. , 2018, Cancer discovery.

[12]  M. Loh,et al.  Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. , 2018, Blood.

[13]  P. Richardson,et al.  CD38 antibodies in multiple myeloma: back to the future. , 2018, Blood.

[14]  K. Goldberg,et al.  FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy , 2017, The oncologist.

[15]  Huipin Yuan,et al.  A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  P. Hari,et al.  Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma. , 2016, The New England journal of medicine.

[17]  T. Luetkens,et al.  Immunotherapies targeting CD38 in Multiple Myeloma , 2016, Oncoimmunology.

[18]  Renier J. Brentjens,et al.  Driving CAR T-cells forward , 2016, Nature Reviews Clinical Oncology.

[19]  P. Parren,et al.  Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma , 2015, Haematologica.

[20]  R. Groen,et al.  Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab , 2015, Leukemia.

[21]  Yu-jing Zhang,et al.  CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type , 2015, Annals of Hematology.

[22]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[23]  J. Laubach,et al.  Daratumumab granted breakthrough drug status , 2014, Expert opinion on investigational drugs.

[24]  O. Shpilberg,et al.  Retinoic acid induces adhesion and migration in NB4 cells through Pyk2 signaling. , 2013, Leukemia research.

[25]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[26]  R. Morgan,et al.  Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry , 2012, Journal of Translational Medicine.

[27]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[28]  Jeffrey D Varner,et al.  Interferon regulatory factor-1 binds c-Cbl, enhances mitogen activated protein kinase signaling and promotes retinoic acid-induced differentiation of HL-60 human myelo-monoblastic leukemia cells , 2011, Leukemia & lymphoma.

[29]  H. Nakamine,et al.  Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab , 2009, International journal of hematology.

[30]  W. Wilson,et al.  Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor , 2008 .

[31]  M. Lichtman.  Battling the hematological malignancies: the 200 years' war. , 2008, The oncologist.

[32]  D. Catovsky,et al.  Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH , 2007, British journal of haematology.

[33]  L. Medeiros,et al.  Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. , 2005, American journal of clinical pathology.

[34]  D. Rawlings,et al.  CD38 Signaling Regulates B Lymphocyte Activation via a Phospholipase C (PLC)-γ2-Independent, Protein Kinase C, Phosphatidylcholine-PLC, and Phospholipase D-Dependent Signaling Cascade1 , 2005, The Journal of Immunology.

[35]  Yuan-fang Liu,et al.  All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  K. Kawa,et al.  Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells , 2004, Leukemia.

[37]  G. Tricot,et al.  Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. , 2004, American journal of clinical pathology.

[38]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[39]  V. Diehl,et al.  Challenges in treating hematologic malignancies. , 2002, Seminars in oncology.

[40]  C. Bloomfield,et al.  All-trans-Retinoic Acid in Acute Promyelocytic Leukemia , 2000 .

[41]  G Shubinsky,et al.  The CD38 lymphocyte differentiation marker: new insight into its ectoenzymatic activity and its role as a signal transducer. , 1997, Immunity.